A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x.

Yunxin Chen^#^{1

2}, Sathish Kumar Gopalakrishnan^#^{1

3}, Melissa Ooi⁴, Rehena Sultana⁵, Li Hui Lim¹, Nicholas Grigoropoulos^{1

2}, Shin Yeu Ong^{1

2}, Mingge Xu⁴; SGHMM1 Investigators; Wee Joo Chng^{4

6}, Yeow Tee Goh^{1

2}, Chandramouli Nagarajan^{7

8}

SGHMM1 Investigators:
Ee Mei Teh, Melinda Tan, Lawrence Ng, Yuh Shan Lee, Colin Phipps, Francesca Lorraine W Y Lim, William Hwang

¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
² SingHealth Duke-NUS Blood Cancer Center, Singapore, Singapore.
³ Department of Haematology, Health Sciences North, Sudbury, ON, Canada.
⁴ Department of Haematology, National University Hospital, Singapore, Singapore.
⁵ Centre for Quantitative Medicine, DUKE-NUS Medical School, Singapore, Singapore.
⁶ Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁷ Department of Haematology, Singapore General Hospital, Singapore, Singapore. [email protected].
⁸ SingHealth Duke-NUS Blood Cancer Center, Singapore, Singapore. [email protected].

^# Contributed equally.

No abstract available

Publication types